M. Chida

发表

CYP2D6.10 present in human liver microsomes shows low catalytic activity and thermal stability.

T. Kamataki, Katsunori Nakamura, S. Ohgiya, 2002, Biochemical and biophysical research communications.

Is the Monkey an Appropriate Animal Model to Examine Drug-Drug Interactions Involving Renal Clearance? Effect of Probenecid on the Renal Elimination of H2 Receptor Antagonists

H. Kusuhara, Y. Sugiyama, E. Fuse, 2006, Journal of Pharmacology and Experimental Therapeutics.

Detection of Three Genetic Polymorphisms in the 5′‐Flanking Region and Intron 1 of Human CYP1A2 in the Japanese Population

J. Yokota, T. Kamataki, T. Yokoi, 1999, Japanese journal of cancer research : Gann.

New allelic arrangement CYP2D6*36 x 2 found in a Japanese poor metabolizer of debrisoquine.

T. Kamataki, N. Nemoto, T. Yokoi, 2002, Pharmacogenetics.

Olopatadine ameliorates rat experimental cutaneous inflammation by improving skin barrier function.

T. Tamura, T. Amano, M. Chida, 2008, Pharmacology.

Olopatadine Ameliorates Rat Experimental Cutaneous Inflammation by Improving Skin Barrier Function

T. Tamura, T. Amano, M. Chida, 2007, Pharmacology.

A new CYP2D6 allele with a nine base insertion in exon 9 in a Japanese population associated with poor metabolizer phenotype.

T. Kamataki, F. Gonzalez, K. Chiba, 1996, Pharmacogenetics.

Genetic polymorphism of CYP2D6 in the Japanese population.

J. Yokota, T. Kamataki, F. Gonzalez, 1999, Pharmacogenetics.

A new variant CYP2D6 allele (CYP2D6*21) with a single base insertion in exon 5 in a Japanese population associated with a poor metabolizer phenotype.

T. Kamataki, N. Nemoto, T. Yokoi, 1999, Pharmacogenetics.

Analysis of the CYP2D6 gene in relation to dextromethorphan O‐demethylation capacity in a Japanese population

T. Kamataki, Shinichi Kobayashi, T. Tateishi, 1999, Clinical pharmacology and therapeutics.

The UGT1A1*28 allele is relatively rare in a Japanese population.

H. Saka, T. Kamataki, K. Nakayama, 1998, Pharmacogenetics.